Decitabine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Decitabine: From Myelodysplastic Syndrome to Refractory Cytopenia of Childhood
One-Sentence Summary
Decitabine is a DNA hypomethylating agent internationally approved for myelodysplastic syndrome (MDS), acting by inhibiting DNA methyltransferase (DNMT) enzymes to reverse aberrant epigenetic silencing in hematopoietic progenitor cells. The TxGNN model predicts it may be effective for Refractory Cytopenia of Childhood (RCC) — a pediatric MDS subtype defined by severe multilineage cytopenia — with a mechanistic rationale rooted in shared epigenetic pathology. Currently only 1 retrospective cohort study supports this direction; no dedicated clinical trials for this specific indication have been registered.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Internationally approved for MDS — not registered in Taiwan (0 authorizations) |
| Predicted New Indication | Refractory Cytopenia of Childhood |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data source. Based on known information, Decitabine is a nucleoside analog belonging to the DNA hypomethylating agent (HMA) class. Its established efficacy in myelodysplastic syndrome is mechanistically driven by inhibition of DNMT1, DNMT3A, and DNMT3B enzymes, which leads to re-expression of epigenetically silenced tumor suppressor genes — including CDKN2B/p15, CDH1, and RASSF1A — thereby restoring normal hematopoietic differentiation and triggering apoptosis in dysplastic progenitor cells.
Refractory Cytopenia of Childhood (RCC) is classified under the WHO pediatric MDS framework and represents the most common pediatric MDS subtype. Its core pathology — aberrant DNA methylation of hematopoietic stem and progenitor cell regulatory genes — directly overlaps with the molecular target of Decitabine. This biological continuity between adult MDS and pediatric RCC provides a credible mechanistic foundation for the TxGNN prediction, as both conditions share the hallmark of epigenetic dysregulation driving ineffective hematopoiesis.
That said, the pediatric context introduces critical caveats. Children with RCC typically present with lower bone marrow reserves, a narrower therapeutic window for myelosuppressive agents, and different pharmacokinetic profiles compared to adult MDS patients. The available evidence remains limited to a bridging-to-transplant context rather than standalone therapy, and no dedicated Phase 1/2 trial has been conducted in RCC. Further investigation is needed before extrapolating adult MDS dosing protocols to this population.
Clinical Trial Evidence
Currently no related clinical trials registered for Refractory Cytopenia of Childhood.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35624441 | 2022 | Retrospective Cohort | BMC Pediatrics | Single-center 10-year experience with Decitabine combined minimally myelosuppressive regimen (DAC + MMR) as bridging therapy to allo-HSCT in children with MDS (including RCC). Reports feasibility and transplant outcomes, supporting Decitabine’s role as a pre-transplant cytoreductive strategy in the pediatric setting. |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic — Nucleoside analog / DNA Hypomethylating Agent (fluoropyrimidine-like mechanism via DNMT incorporation) |
| Myelosuppression Risk | High — neutropenia, thrombocytopenia, and anemia are the most common dose-limiting toxicities; particularly hazardous in RCC patients who already present with baseline multilineage cytopenia |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | CBC with differential (at minimum weekly during induction cycles), serum creatinine, liver function tests (ALT, AST, bilirubin), electrolytes |
| Handling Protection | Must follow cytotoxic drug handling regulations; appropriate PPE (gloves, gown, eye protection) required during preparation and administration |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: Only one retrospective cohort study documents Decitabine use in pediatric MDS (encompassing RCC), limited to a bridge-to-transplant context with a small patient cohort. While the mechanistic rationale is biologically sound and the analogy to adult MDS is compelling, the current evidence base is insufficient to support proceeding toward clinical application in RCC without purpose-built investigation.
To proceed, the following is needed:
- A dedicated Phase 1/2 clinical trial evaluating Decitabine in pediatric RCC (as a distinct entity from broader pediatric MDS)
- Pediatric pharmacokinetic/pharmacodynamic data to inform dose adjustment from adult MDS protocols
- Detailed mechanism of action data (MOA) sourced from DrugBank or primary pharmacology literature
- A pediatric-specific safety monitoring plan accounting for pre-existing baseline cytopenias
- Assessment of Taiwan regulatory pathway for compassionate use or orphan drug designation in this rare pediatric indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.